Timothy Tyson Net Worth

The estimated Net Worth of Timothy Tyson is at least $103 Mille dollars as of 29 September 2022. Mr. Tyson owns over 16,932 units of Tyme Technologies Inc stock worth over $7,729 and over the last 7 years he sold TYME stock worth over $0. In addition, he makes $94,860 as Independent Director at Tyme Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Tyson TYME stock SEC Form 4 insiders trading

Timothy has made over 2 trades of the Tyme Technologies Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 16,932 units of TYME stock worth $105,994 on 29 September 2022.

The largest trade he's ever made was buying 16,932 units of Tyme Technologies Inc stock on 29 September 2022 worth over $105,994. On average, Timothy trades about 1,471 units every 134 days since 2017. As of 29 September 2022 he still owns at least 24,932 units of Tyme Technologies Inc stock.

You can see the complete history of Mr. Tyson stock trades at the bottom of the page.

Timothy Tyson biography

Timothy C. Tyson serves as Independent Director of the Company. He has been a member of our Board since March 2015. Mr. Tyson is currently Chairman and CEO of TriRx Pharmaceutical Services, LLC and Chairman at Icagen Inc. He served as Chairman and CEO of Avara Pharmaceutical Services from May 2015 to October 2018. He served as Chief Executive Officer and Executive Chairman of Aptuit from 2008 to 2012 and non-executive Chairman from 2012 to 2016. Mr. Tyson served as the Chief Executive Officer of Valeant Pharmaceuticals International (formerly, ICN Pharmaceuticals Inc.) from January 1, 2005 to February 1, 2008. He served as President of Valeant Pharmaceuticals International from November 2002 to February 1, 2008 and served as its Chief Operating Officer from November 2002 to December 2004. He served as President of Global Manufacturing and Supply for GlaxoSmithKline plc. from June 1998 to November 2002. From 1997 to 1998, Mr. Tyson served as GlaxoSmithKline’s Vice President and General Manager of Business Operations. During his 14-year tenure at GlaxoSmithKline, he served in a variety of roles with broad international and domestic responsibilities, including significant management experience running two divisions: Glaxo Dermatology and Cerenex Pharmaceuticals. He was responsible for managing all sales and marketing for the U.S. operations, where he launched over 30 new products. Prior to his tenure at GlaxoSmithKline, Mr. Tyson served in a number of executive positions at Bristol-Myers Company in Operations and Research and Development. Before his tenure at Bristol-Myers, he served as a Manufacturing Manager for Procter & Gamble. He served as an Officer in the United States Army from 1974 to 1979 and spent 14 years in the United States Army Reserves. He has been Independent Non-Executive Chairman of Icagen, formerly Caldera Pharmaceuticals, since April 1, 2014 and has been a director since October 2013.

What is the salary of Timothy Tyson?

As the Independent Director of Tyme Technologies Inc, the total compensation of Timothy Tyson at Tyme Technologies Inc is $94,860. There are 10 executives at Tyme Technologies Inc getting paid more, with James Biehl having the highest compensation of $1,500,980.

How old is Timothy Tyson?

Timothy Tyson is 68, he's been the Independent Director of Tyme Technologies Inc since 2015. There are 2 older and 16 younger executives at Tyme Technologies Inc. The oldest executive at Tyme Technologies Inc is Gerald Sokol, 77, who is the Independent Director.

What's Timothy Tyson's mailing address?

Timothy's mailing address filed with the SEC is C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA, 02140.

Insiders trading at Tyme Technologies Inc

Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian e Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.

What does Tyme Technologies Inc do?

Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.

With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.

Complete history of Mr. Tyson stock trades at Biodelivery Sciences International, Syros Pharmaceuticals e Tyme Technologies Inc

Tyme Technologies Inc executives and stock owners

Tyme Technologies Inc executives and other stock owners filed with the SEC include:

• James Biehl,
  Chief Legal Officer and Corporate Secretary
• Michele Korfin,
  Chief Operating Officer
• Steve Hoffman,
  Chairman of the Board, Chief Executive Officer, Chief Science Officer
• Steven E. Hoffman,
  Co-Founder, Chairman & Chief Science Officer
• James Biehl J.D.,
  Chief Legal Officer & Sec.
• Dr. Jonathan M. Eckard,
  Chief Bus. Officer
• Richard Cunningham,
  CEO & Director
• David Carberry,
  Independent Director
• Donald Degolyer,
  Independent Director
• Gerald Sokol,
  Independent Director
• Timothy Tyson,
  Independent Director
• Douglas Michels,
  Independent Director
• Paul Sturman,
  Independent Director
• Jonathan Eckard,
  Chief Business Officer
• Giuseppe Del Priore,
  Chief Medical Officer
• Barbara Galaini,
  Principal Financial Officer, Principal Accounting Officer, Corporate Controller
• Frank L. Porfido,
  Chief Financial Officer
• Dr. Jan Marie-Albert Van Tornout M.D., M.Sc.,
  Acting Chief Medical Officer
• Dr. John M. Rothman,
  Exec. VP of Product Devel.
• John Zucaro P.E.,
  Sr. VP of CMC
• Tommy G Thompson,
  Director
• Christine D. Baker,
  Director
• John M. Rothman,
  EVP, Product Development
• Michael Demurjian,
  10% owner
• Ben R Taylor,
  President, CFO
• Tornout Jan M Van,
  Acting Chief Medical Officer
• Christopher F Brown,
  10% owner
• Frank L. Porfido,
  Chief Financial Officer
• Richard Anthony Cunningham,,
  Chief Executive Officer